Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Mimbari who wrote (11923)	5/13/2013 4:44:50 PM
From: dirkdiggler	1 Recommendation Respond to of 13111

OK. But, when are we going to hear about a deal. I was on a conference call in Nov. 2010 and heard Peter say a PH-10 deal was not a matter of if but when. OK. When? This was over 2 years ago and I'm down 40%.

To: Mimbari who wrote (11923)	5/13/2013 5:45:07 PM
From: jm2i123	Respond to of 13111

I totally agree. Arguing about PVCT to go to ASCO is like trying to make the case to send a brand new Ferrari to the garage when there's nothing to do on it. ASCO is the place to go for 1/Releasing data This year ASCO will be literally owned by BMS who will publish long awaited phase III data. 2/Own the space (big stands, big pr, basically big pharma) 3/Making a splash - or trying to do it - for New Biotechs (and burning half of the seed money in one shot) Everybody in the Industry knows Provectus. They have more interesting stuff to do than "networking" at ASCO. NTTG is just a Med agency guy whose goal in life is a free ticket and hotel pass at ASCO. He will attend as "visitor" and do "some networking". The "told you saw"...expert will be literally mutated in a "I was there" business cards hero...the usual, average, mediocre Med com employee.